# NCT06049576 (NCT06049576)

> Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06049576
- Phase: PHASE1
- Status: SUSPENDED
- Sponsor: City of Hope Medical Center
- Conditions: Clear Cell Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions: Biospecimen Collection; Bone Scan; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Myrciaria dubia Prebiotic Supplement; Nivolumab
- Enrollment: 31
- Primary outcome: Abundance of ruminococcus in the stool

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 13
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct06049576

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06049576", "email": "<work email>"}; the inbox owner confirms by the emailed link.